Medical Advocates

Tenofovir Disoproxil Fumarate
Perinatal Data

Journal Citations
Conference Citations


Tenofovir Main Page Main New/Newsworthy  Home Page      

Last Update:  November 12, 2016
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

Journal Papers, Abstracts, and Commentaries


Tenofovir Disoproxil Fumarate Safety for Women and their Infants during Pregnancy and Breastfeeding: Systematic Review.
Mofenson LM, Baggaley RC, Mameletzis I. 
AIDS. 2016 Nov 7.

Tenofovir exposure in utero and linear growth in HIV exposed, uninfected infants: a prospective study.
M le Roux S, Jao J, Brittain K, . et al
. 2016 Oct 14.

Serum phosphate and creatinine levels in the first year of life in infants born to HIV-positive mothers receiving tenofovir-based combination regimens during pregnancy and prolonged breastfeeding in an option B+ programme in Malawi.
Floridia M, Liotta G, Andreotti M,  et al

J Acquir Immune Defic Synd
. 2016 Aug 24

In-utero exposure to tenofovir is associated with impaired fetal and infant growth: need for follow-up studies in combination antiretroviral therapy/HIV-exposed infants.
Denneman L, Cohen S, Godfried MH,  et al

2016 Aug 24;30(13):2135-7

Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen.
Jourdain G, Ngo-Giang-Huong N, Cressey TR,  et al
BMC Infect Dis
. 2016 Aug 9;16:393.

Detectable tenofovir levels in breastfeeding infants of mothers exposed to topical tenofovir.
Noguchi LM, Montgomery ET, Biggio JR,
Antimicrob Agents Chemother. 2016 Jul 11.

Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Palombi L, Pirillo MF, Marchei E, et al 

J Antimicrob Chemother
. 2015 Dec 17.

Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV.
Wang J, Liu J, Qi C, Yan T, et al

Antivir Ther
. 2015 Jul 28

Lower Newborn Bone Mineral Content Associated with Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.
Siberry GK, Jacobson DL, Kalkwarf HJ, et al
Clin Infect Dis. 2015 Jun 9. pii: civ437

Pharmacokinetics of tenofovir during pregnancy and postpartum.
Best BM, Burchett S, Li H,
 et al
. 2015 May 11.

Pharmacokinetics of Once versus Twice Daily Darunavir In Pregnant HIV-Infected Women.
Stek A, Best BM, Wang J,  et al

J Acquir Immune Defic Syndr
. 2015
May 6

Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Mansoor LE, Karim QA, Mngadi KT, et al

. 2014 Dec 19;15(1):496.

Use of Tenofovir Disoproxil Fumarate in Highly Viremic, Hepatitis B Mono-Infected Pregnant Women.
Tsai PJ, Chang A, Yamada S, et al.

Dig Dis Sci
. 2014 Jun 5.

Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of Hepatitis B Virus
Greenup AJ, Tan PK, Nguyen V,  et al

J Hepatol
. 2014 May 3.

Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy.
Ransom CE, Huo Y, Patel K, et al; P1025 Team of the International Maternal Pediatric Adolescent AIDS Clinical Trials Group
J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):374-81.

Safety of tenofovir during pregnancy for the mother and fetus: A systematic review.
Wang L, Kourtis AP, Ellington S,et al
Clin Infect Dis
. 2013 Sep 17.

Pharmacokinetics and Safety of Tenofovir in HIV-infected Women during Labor and their Infants During the First Week of Life.
Mirochnick M, Taha T, Kreitchmann R,  et al
J Acquir Immune Defic Syndr
. 2013 Aug 23


Tenofovir useand pregnancy among women initiating HAART.
Maskew M, Westreich D, Firnhaber C, Sanne I.
. 2012 Aug 28

Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial.
Gibb DM, Kizito H, Russell EC,  et al
PLoS Med
. 2012 May;9(5):e1001217

Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.
Siberry GK, Williams PL, Mendez H,  et al 
AIDS. 2012 Feb 29

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
Viganò A, Mora S, Giacomet V,  et al 
Antivir Ther. 2011;16(8):1259-66

Pregnancy-Related effects on Tenofovir Pharmacokinetics: A Population Study with 186 women.
Benaboud S, Hirt D, Launay O, et al
Antimicrob Agents Chemother
. 2011 Nov 28.

Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 - Step 2).
Hirt D, Ekouévi DK, Pruvost A,  et al
Antimicrob Agents Chemother. 2011 Apr 4.

Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1:is it time to move on from zidovudine?
Foster C, Lyall H, Olmscheid B, et al

. 2009 May 11.

Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.
Nurutdinova D, Onen NF, Hayes E, et al 
Ann Pharmacother.
2008 Nov;42(11):1581-5.

Population Pharmacokinetics of Tenofovir in HIV-1-Infected Pregnant Women and Their Neonates (ANRS 12109).
Hirt D, Urien S, Ekouévi D, et al

Clin Pharmacol
Ther. 2008 Nov 5

Conference Reports, Abstracts, and Posters

XIX International AIDS Conference

Association of tenofovir disoproxil fumarate with neonatal growth
C. Ransom, Y. Huo, K. Patel, et al


Association of tenofovir disoproxil fumarate with neonatal growth
C. Ransom, Y. Huo, K. Patel., et al


Tenofovir Main Page Main New/Newsworthy  Home Page      

Tenofovir Perinatal Data